EP1631680A2 — Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
Assigned to Bayer AG · Expires 2006-03-08 · 20y expired
What this patent protects
The invention provides a human DPP4 which is associated with the cardiovascular disorders, dermatological disorders, cancer disorders, hematological disorders, respiratory diseases, gastrointestinal and liver diseases, urological disorders and metabolic diseases. The invention al…
USPTO Abstract
The invention provides a human DPP4 which is associated with the cardiovascular disorders, dermatological disorders, cancer disorders, hematological disorders, respiratory diseases, gastrointestinal and liver diseases, urological disorders and metabolic diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, cancer disorders, hematological disorders, respiratory diseases, gastrointestinal and liver diseases, urological disorders and metabolic diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of DPP4 as well as pharmaceutical compositions comprising such compounds.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.